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Abstract Colorectal cancer (CRC) is one of the most com-
mon cancers worldwide, and many patients are already at an
advanced stage when they are diagnosed. Therefore, novel
biomarkers for early detection of colorectal cancer are re-
quired. In this study, we performed a global shotgun proteo-
mic analysis using formalin-fixed and paraffin-embedded
(FFPE) CRC tissue. We identified 84 candidate proteins
whose expression levels were differentially expressed in can-
cer and non-cancer regions. A label-free semiquantitative
method based on spectral counting and gene ontology (GO)
analysis led to a total of 21 candidate proteins that could po-
tentially be detected in blood. Validation studies revealed
cyclophilin A, annexin A2, and aldolase AmRNA and protein
expression levels were significantly higher in cancer regions
than in non-cancer regions. Moreover, an in vitro study
showed that secretion of aldolase A into the culture medium
was clearly suppressed in CRC cells compared to normal co-
lon epithelium. These findings suggest that decreased aldolase
A in blood may be a novel biomarker for the early detection of
CRC.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers
worldwide. If the tumor is limited to the mucosa or submuco-
sa, CRC can be completely cured by endoscopic or surgical
therapy; however, many patients are already at an advanced
stage when they are diagnosed. Therefore, an early detection
method is needed. Diagnostic blood tests based on detection
of carcinoembryonic antigen (CEA) are now widely used for
CRC, but the sensitivity of this biomarker in early-stage can-
cer is only 5–10% [1, 2]. The identification of novel candidate
molecules that are secreted by cancer cells may lead to the
development of early detection methods and improved
prognosis.
Formalin-fixed and paraffin-embedded (FFPE) tissues
are archived in hospitals, together with detailed clinical
information such as disease history, clinical examination
results, and drug responses. FFPE tissues are routinely
used in the diagnosis and research of diseases, including
cancers, by conventional staining, immunohistochemistry
(IHC), and in situ hybridization [3–5]. Previously, FFPE
tissues were considered unsuitable for proteomic analysis.
However, methods to isolate protein from FFPE tissues
for proteomic analysis have been developed, and various
FFPE tissues have been used in proteomic studies [6–17].
Thus, archived FFPE tissues may be useful for identifying
new biomarkers.
In this study, we performed shotgun liquid chromatography
(LC)/mass spectrometry (MS)-based global proteomic analy-
sis using proteins from FFPE CRC tissue to identify proteins
whose expression levels are modified in cancer regions. We
identified aldolase A as a candidate protein with potential as a
novel biomarker for early detection of CRC.
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The following materials were purchased from Wako Pure
Chemical Industries (Osaka, Japan): guanidine hydrochlo-
ride, DTT, Tris, tris (2-carboxyethyl) phosphine hydro-
chloride (TCEP), and iodoacetamide (IAA). All other
chemicals and reagents were purchased from Sigma
Chemical Corp. (St. Louis, MO, USA).
Patients and tissue specimens
The tissues used in this study were from 45 patients who
underwent surgical resection for CRC at Nippon Medical
School Hospital between October 2007 and August 2014.
None of the patients received chemotherapy or radiation ther-
apy prior to surgery and none had inflammatory colorectal
disease such as colitis or infectious diseases. The pathological
diagnosis and clinicopathological stage were determined ac-
cording to the criteria of the World Health Organization [18].
After a histopathological analysis, 10 of these 45 cases were
selected for proteomic analysis. Immunohistochemical analy-
ses were performed on all 45 cases. Paraffin-embedded spec-
imens were prepared for proteomic and immunohistochemical
analyses. This study was carried out in accordance with the
principles embodied in the Declaration of Helsinki, 2013, and
the Japanese Society of Pathology Ethics Committee.
Informed consent for the use of colorectal tissues was obtain-
ed from all patients.
Protein extraction from FFPE tissue
FFPE CRC tissues from ten patients were used for proteomic
analysis. Pathological and clinical information are shown in
Table 1. Following histological examination of hematoxylin
and eosin (H&E) sections, we separated the cancer regions
from the non-cancer regions, which maintained normal struc-
tures. Sections (10 μm) were deparaffinized in xylene and
rehydrated through a series of graded alcohols (100, 90, 80,
and 70 %). After staining with Mayer’s hematoxylin for
5 min, cancer and non-cancer regions weremanually dissected
under a microscope (Fig. 1). Proteins were extracted from
both cancer and non-cancer regions using lysis buffer (6 M
guanidine-HCl, 40 mM Tris-HCl pH 8.2, and 65 mM DTT)
according to a previous report [17]. Protein concentration was
measured by the Bradford method.
In-solution trypsin digestion
A gel-free digestion was performed according to the protocol
described by Bluemlein et al. [19], with slight modifications.
Briefly, 10 μg of protein was extracted from each sample,
reduced with 45 mM DTT and 20 mM TCEP, and then
alkylated using 100 mM IAA. After alkylation, samples were
digested with proteomics-grade trypsin (Agilent Technologies
Inc., Santa Clara, CA, USA) at 37 °C for 24 h. Digests were
purified using PepClean C-18 Spin Columns (Thermo,
Rockford, IL, USA) according to the manufacturer’s protocol.
LC-MS/MS analysis for protein identification
Approximately 2 μg of purified peptide samples were injected
onto a peptide L-trap column (Chemicals Evaluation and
Research Institute, Tokyo, Japan) using an HTS PAL
autosampler (CTC Analytics, Zwingen, Switzerland) and fur-
ther separated thorough an Advance-nano UHPLC (AMR
Inc., Tokyo, Japan) using a reverse-phase C18-column
(Zaplous column α, 3-μm diameter gel particles and 100 Å
pore size, 0.1 × 150 mm; AMR). The mobile phase consisted
of solution A (0.1 % formic acid in water) and solution B
(acetonitrile). The flow rate was 500 nL/min, with a concen-
tration gradient of acetonitrile from 5 % B to 35 % B over
120 min. Gradient-eluted peptides were analyzed using an
amaZon ETD ion-trap mass spectrometer (Bruker Daltonics,
Billerica, MA, USA). Data were acquired in a data-dependent
manner, in which MS/MS fragmentation was performed on
the ten most intense peaks of every full MS scan.
All MS/MS spectra data were searched against the
SwissProt Homo sapiens database with Mascot (ver-
sion_2.3.01; Matrix Science, London, UK). Search criteria
were as follows: enzyme, trypsin; allowance of up to two
missed cleavage peptides; mass tolerance ±0.5 Da and MS/
MS tolerance ±0.5 Da; and modifications of cysteine carba-
midomethylation, methionine oxidation, and N-formylation
including formyl (K), formyl (R), and formyl (N terminus).
Spectral counting analysis of identified proteins
To compare protein expression across all tissue samples, we used
the spectral counting method. In this analysis, when not specific
spectral peak could be identified, the expression level of that
protein was taken as zero, as described in a previous report
[20]. Fold-changes of expressed proteins in the base 2 logarith-
mic scale were calculated with Rsc based upon spectral counting
[21]. Relative amounts of identified proteins were also calculated
with the normalized spectral abundance factor (NSAF) [22].
Candidate proteins with modified expression levels in the cancer
region were chosen to ensure that the Rsc satisfied >1 or <−1,
which corresponded to fold changes of >2 or <0.5.
Bioinformatics
Functional annotations for the identified proteins with
modified expression levels in the cancer region were proc-
essed using the Database for annotation, visualization, and
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integrated discovery (DAVID) version 6.7 (http://david.
abcc.ncifcrf.gov/home.jsp) [23–25].
Quantitative RT-PCR
Total RNA was extracted from FFPE CRC tissue with the
RNeasy FFPE Kit (QIAGEN, Valencia, CA, USA) and from
CRC cell lines with the GenElute Mammalian Total RNA
Miniprep Kit (Sigma). cDNA was synthesized using the
SuperScript VILO cDNA Synthesis Kit for FFPE tissue and
the High Capacity cDNA Reverse Transcription kit for the
CRC cell line according to the manufacturer’s protocols
(Life Technologies Japan, Tokyo, Japan). To measure expres-
sion of aldolase A, cyclophilin A, and annexin A2 mRNA,
quantitative reverse transcription PCR (qRT-PCR) was per-
formed with the 7500 system (Applied Biosystems, Foster
City, CA, USA). Primers and TaqMan probes for aldolase A
(Hs00765620_m1), cyclophilin A (Hs04194521_s1), annexin
A2 (Hs00743063_s1), and 18S rRNA (Hs03928990_g1)
were used with the TaqMan Gene Expression Assay. qRT-
PCR results were expressed relative to an internal standard
concentration as a ratio of target/18S rRNA. Gene expression
was measured in triplicate.
Immunohistochemistry
FFPE CRC tissues from 46 patients were used for a val-
idation analysis. Pathological and clinical information are
Table 1 Clinical and
pathological data of patients with
CRC that contributed tissues for
proteomic analysis






1 63 M T3N0M0 Stage IIA S 49 26
2 53 M T3N0M0 Stage IIA S 38 38
3 77 F T3N0M0 Stage IIA S 50 34
4 53 M T3N0M0 Stage IIA S 69 52
5 76 F T3N0M0 Stage IIA S 52 22
6 51 M T3N0M0 Stage IIA A 22 4
7 67 F TisN0M0 Stage 0 A 44 28
8 52 M T3N0M0 Stage IIA Ra 52 50
9 69 M T3N0M0 Stage IIA T 65 16
10 69 F T3N0M0 Stage IIA S 19 35
M male, F female, A ascending colon, T transverse colon, S sigmoid colon, Ra upper rectum
Fig. 1 Manual dissection of
FFPE colon tissue.
Representative image shows non-
cancer and cancer regions before
(a and b, respectively) and after (c
and d, respectively) dissection.
Sections were stained with
hematoxylin
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shown in Table 2. Paraffin-embedded tissue sections
(3 μm) were subjected to immunostaining using a
Histofine Simple Stain MAX-PO (R) kit (Nichirei,
Tokyo, Japan) for identifying aldolase A, annexin A2,
and cyclophilin A. After deparaffinization, sections were
pretreated in an autoclave at 121 °C for 15 min in 10 mM
citrate buffer (pH 6.0) for cyclophilin A. Endogenous per-
oxidase activity was blocked by incubation for 30 min
with 0.3 % hydrogen peroxide in methanol. Tissue sec-
tions were then incubated with the anti-ALDOA antibody
(1:150 dilution; Atlas Antibodies, Stockholm, Sweden)
for aldolase A, anti-cyclophilin A antibody (1:150 dilu-
tion; Novus Biologicals, Littleton, CO, USA), or anti-
annexin A2 antibody (1:400 dilution; Cell Signaling
Technology, Inc., Danvers, MA, USA) in phosphate-
buffered saline containing 1 % bovine serum albumin
for 16 h at 4 °C. Bound antibodies were detected with
the Simple Stain MAX-PO (R) with diaminobenzidine
tetrahydrochloride as the substrate. Sections were then
counterstained with Mayer’s hematoxylin. Two investiga-
tors (TY and HT) evaluated all the sections separately in a
blinded manner. Sections were scored for both intensity
(0, no stain; 1, weak; 2, moderate; and 3, strong) and
percentage of epithelial cells that stained positive (0, 0–
5 %; 1, 6–25 %; 2, 26–50 %; 3, 51–75 %; and 4, 76–
100 %). Scores were derived from the sum of the intensity
and percentage of immunoreactive cells [15].
Table 2 Clinical and pathological data of patients with CRC that
contributed tissues for immunohistochemical analysis
Patient No. Age
(year)
Gender pTNM pStaging Tumor
location
1 67 F TisN0M0 Stage 0 A
2 66 F TisN0M0 Stage 0 D
3 61 F TisN0M0 Stage 0 S
4 70 M TisN0M0 Stage 0 T
5 64 F TisN0M0 Stage 0 T
6 63 M T2N0M0 Stage I Rb
7 58 F T2N0M0 Stage I Rb
8 45 F T2N0M0 Stage I Rb
9 67 F T2N0M0 Stage I Ra
10 87 F T2N0M0 Stage I Ra
11 67 F T2N0M0 Stage I S
12 70 M T1N0M0 Stage I S
13 75 F T1N0M0 Stage I T
14 82 M T1N0M0 Stage I T
15 63 M T3N0M0 Stage IIA S
16 53 M T3N0M0 Stage IIA S
17 77 F T3N0M0 Stage IIA S
18 53 M T3N0M0 Stage IIA S
19 76 F T3N0M0 Stage IIA S
20 51 M T3N0M0 Stage IIA A
21 52 M T3N0M0 Stage IIA Ra
22 69 M T3N0M0 Stage IIA T
23 69 F T3N0M0 Stage IIA S
24 92 M T3N0M0 Stage IIA T
25 64 M T2N1aM0 Stage IIIA Ra
26 73 F T2N1bM0 Stage IIIA Ra
27 64 M T3N1aM0 Stage IIIB Ra
28 50 F T3N1bM0 Stage IIIB S
29 51 M T3N1bM0 Stage IIIB A
30 64 M T3N1aM0 Stage IIIB S
31 64 F T3N1bM0 Stage IIIB Ra
32 78 F T3N1aM0 Stage IIIB A
33 72 F T4aN1AM0 Stage IIIB C
34 52 M T3N1bM0 Stage IIIB Ra
35 85 F T4bN1aM0 Stage IIIC A
36 70 M T4aN2aM0 Stage IIIC S
37 81 F T4aN0M1a Stage IVA T
38 71 F T4aN2aM1a Stage IVA A
39 49 M T3N2aM1a Stage IVA C
40 78 M T3N1bM1a Stage IVA Ra
41 77 M T4aN2aM1a Stage IVA T
42 57 M T3N2bM1b Stage IVB Ra
43 72 F T4aN0M1b Stage IVB D
44 71 F T4bN2bM1b Stage IVB C
45 70 M T3N0M1b Stage IVB S
M male, F female, A ascending colon, T transverse colon, S sigmoid
colon, Ra upper rectum, Rb lower rectum, D descending colon, C cecum
Fig. 2 Venn map of proteins identified from FFPE colorectal cancer
tissue. We identified 204 proteins in the cancer regions and 142 in the
non-cancer regions
Fig. 3 Semiquantitative comparison of proteins identified in FFPE colon
tissue. Rsc and normalized spectral abundance factor (NSAF) values
calculated for the proteins identified (x-axis). Comparison of protein ex-
pression in cancer versus non-cancer tissue. Proteins highly expressed in
either cancer or non-cancer regions were plotted near the right or left side
of the x-axis
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Table 3 Differentially expressed proteins in cancer region of CRC samples
No. ID Accession number and description No. of amino
acids
Spectral counting
Non-cancer Cancer Fold change
(Rsc)
1 FCGBP_HUMAN (Q9Y6R7) IgGFc-binding protein 5405 15 1 −3.307086
2 K1C10_HUMAN (P13645) Keratin, type I cytoskeletal 10 584 7 0 −3.163409
3 H3C_HUMAN (Q6NXT2) Histone H3.3C 135 12 1 −3.006964
4 CO1A1_HUMAN (P02452) Collagen alpha-1(I) chain 1464 6 0 −2.975121
5 K22E_HUMAN (P35908) Keratin, type II cytoskeletal 2 epidermal 639 5 0 −2.759125
6 K2C6B_HUMAN (P04259) Keratin, type II cytoskeletal 6B 564 5 0 −2.759125
7 H2B1A_HUMAN (Q96A08) Histone H2B type 1-A 127 9 1 −2.630943
8 K1C14_HUMAN (P02533) Keratin, type I cytoskeletal 14 472 4 0 −2.505717
9 K1C17_HUMAN (Q04695) Keratin, type I cytoskeletal 17 432 4 0 −2.505717
10 K2C5_HUMAN (P13647) Keratin, type II cytoskeletal 5 590 4 0 −2.505717
11 CRIP1_HUMAN (P50238) Cysteine-rich protein 1 77 3 0 −2.198995
12 MUC2_HUMAN (Q02817) Mucin-2 5179 3 0 −2.198995
13 ATPA_HUMAN (P25705) ATP synthase subunit alpha, mitochondrial 553 6 1 −2.125742
14 K2C1B_HUMAN (Q7Z794) Keratin, type II cytoskeletal 1b 578 13 4 −1.887275
15 LMNA_HUMAN (P02545) Prelamin-A/C 664 10 3 −1.84682
16 K1C9_HUMAN (P35527) Keratin, type I cytoskeletal 9 623 15 5 −1.827612
17 ACTN4_HUMAN (O43707) Alpha-actinin-4 911 2 0 −1.810107
18 GLUC_HUMAN (P01275) Glucagon 180 2 0 −1.810107
19 RS7_HUMAN (P62081) 40S ribosomal protein S7 194 2 0 −1.810107
20 K2C1_HUMAN (P04264) Keratin, type II cytoskeletal 1 644 39 18 −1.541287
21 CLCA1_HUMAN (A8K7I4) Calcium-activated chloride channel regulator 1 914 7 3 −1.393723
22 CAH1_HUMAN (P00915) Carbonic anhydrase 1 261 1 0 −1.277731
23 GSLG1_HUMAN (Q92896) Golgi apparatus protein 1 1179 1 0 −1.277731
24 LAMB3_HUMAN (Q13751) Laminin subunit beta-3 1172 1 0 −1.277731
25 MK15_HUMAN (Q8TD08) Mitogen-activated protein kinase 15 544 1 0 −1.277731
26 RS30_HUMAN (P62861) 40S ribosomal protein S30 59 1 0 −1.277731
27 ZHANG_HUMAN (Q9NS37) CREB/ATF bZIP transcription factor 354 1 0 −1.277731
28 ZN408_HUMAN (Q9H9D4) Zinc finger protein 408 720 1 0 −1.277731
29 PGBM_HUMAN (P98160) Basement membrane-specific heparan sulfate
proteoglycan core protein
4391 1 0 −1.277731
30 DPYL2_HUMAN (Q16555) Dihydropyrimidinase-related protein 2 572 1 0 −1.277731
31 RL31_HUMAN (P62899) 60S ribosomal protein L31 125 1 0 −1.277731
32 HNRPL_HUMAN (P14866) Heterogeneous nuclear ribonucleoprotein L 589 1 0 −1.277731
33 FLNA_HUMAN (P21333) Filamin-A 2647 1 0 −1.277731
34 CO6A2_HUMAN (P12110) Collagen alpha-2(VI) chain 1019 1 0 −1.277731
35 ARPC5_HUMAN (O15511) Actin-related protein 2/3 complex subunit 5 151 1 0 −1.277731
36 RS23_HUMAN (P62266) 40S ribosomal protein S23 143 1 0 −1.277731
37 MYH14_HUMAN (Q7Z406) Myosin-14 1995 1 0 −1.277731
38 EF2_HUMAN (P13639) Elongation factor 2 858 1 0 −1.277731
39 ECHB_HUMAN (P55084) Trifunctional enzyme subunit beta, mitochondrial 474 1 0 −1.277731
40 FA48A_HUMAN (Q8NEM7) Protein FAM48A 779 1 0 −1.277731
41 SETX_HUMAN (Q7Z333) Probable helicase senataxin 2677 1 0 −1.277731
42 GFAP_HUMAN (P14136) Glial fibrillary acidic protein 432 1 0 −1.277731
43 PERI_HUMAN (P41219) Peripherin 470 1 0 −1.277731
44 POTEE_HUMAN (Q6S8J3) POTE ankyrin domain family member E 1075 1 0 −1.277731
45 TTHY_HUMAN (P02766) Transthyretin 147 1 0 −1.277731
46 CAH2_HUMAN (P00918) Carbonic anhydrase 2 260 1 0 −1.277731
47 ENPL_HUMAN (P14625) Endoplasmin 803 1 0 −1.277731
48 HS71L_HUMAN (P34931) Heat shock 70 kDa protein 1-like 641 1 0 −1.277731
49 CBR1_HUMAN (P16152) Carbonyl reductase [NADPH] 1 277 1 0 −1.277731
50 SPTA2_HUMAN (Q13813) Spectrin alpha chain, brain 2472 1 0 −1.277731
51 HNRCL_HUMAN (O60812) Heterogeneous nuclear ribonucleoprotein C-like 1 293 1 0 −1.277731
52 UGGG1_HUMAN (Q9NYU2) UDP-glucose:glycoprotein glucosyltransferase 1 1555 1 0 −1.277731
53 OST48_HUMAN (P39656) Dolichyl-diphosphooligosaccharide–protein
glycosyltransferase 48 kDa subunit
456 1 0 −1.277731
54 ACTA_HUMAN (P62736) Actin, aortic smooth muscle 377 40 23 −1.238478
55 AGR2_HUMAN (O95994) Anterior gradient protein 2 homolog 175 4 2 −1.124439
56 TBB2C_HUMAN (P68371) Tubulin beta-2C chain 445 12 7 −1.124173
57 KCRB_HUMAN (P12277) Creatine kinase B-type 381 8 5 −1.001492
58 HSP7C_HUMAN (P11142) Heat shock cognate 71 kDa protein 643 1 5 1.051122
59 PPIA_HUMAN (P62937) Peptidyl-prolyl cis-trans isomerase A 165 1 5 1.051122
60 SBP1_HUMAN (Q13228) Selenium-binding protein 1 472 1 5 1.051122
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CRC cell lines
CRC cell lines DLD-1, SW480, and SW620 and normal
human colon epithelial cell line CCD 841 CoN were pur-
chased from the American Type Culture Collection
(Manassas, VA, USA). All cells were cultured in RPMI
1640 medium supplemented with 10 % fetal bovine serum
(FBS) (Gibco, Carlsbad, CA, USA) in an atmosphere con-
taining 5 % CO2.
Protein preparation
CRC cells were plated at a density of 5 × 105 cells per dish in a
100-mm dish and grown in culture medium. After 72 h, cells
were solubilized in urea lysis buffer (7 M urea, 2 M thiourea,
5 % CHAPS, and 1 % Triton X-100). To quantify secreted
protein, the culture medium of CRC cells was collected after
72 h.
Western blot analysis
The cell extract, culture medium, and commercial human
normal serum (ImmunoBioScience Corp., Mukilteo, WA)
were subjected to SDS-PAGE under reducing conditions.
The separated proteins were transferred to polyvinylidene
fluoride transfer membranes. Membranes were incubated
with an anti-annexin A2 rabbit monoclonal antibody, anti-
aldolase A rabbit monoclonal antibody, or anti-cyclophilin
A antibody (Cell Signaling Technology Inc., Beverly,
MA, USA) at 4 °C overnight. Membranes were then
washed and incubated with HRP-conjugated anti-rabbit
IgG antibody (American Qualex, San Clemente, CA).
After washing, blots were visualized by enhanced chemi-
luminescence and detected using a myECL Imager system
(ThermoFisher Scientific). The same membranes were
reprobed with anti-β-actin antibody (Sigma) to confirm
equal loading of the proteins. All Western blot analyses
were performed three times.
Statistical analysis
All data are presented as the mean ± standard error of the
mean. Data between two groups were compared with the un-
paired t test. Values of *P < 0.05 and **P < 0.001 were
considered significant in all analyses. Computations were per-
formed with GraphPad Prism version 5 (GraphPad Software,
La Jolla, CA, USA).
Table 3 (continued)
No. ID Accession number and description No. of amino
acids
Spectral counting
Non-cancer Cancer Fold change
(Rsc)
61 G3P_HUMAN (P04406) Glyceraldehyde-3-phosphate dehydrogenase 335 6 19 1.0692919
62 ANXA2_HUMAN (P07355) Annexin A2 339 1 6 1.2666356
63 MDHM_HUMAN (P40926) Malate dehydrogenase, mitochondrial 338 1 6 1.2666356
64 ALDOA_HUMAN (P04075) Fructose-bisphosphate aldolase A 364 0 3 1.3418115
65 LDHA_HUMAN (P00338) L-lactate dehydrogenase A chain 332 0 3 1.3418115
66 RL7_HUMAN (P18124) 60S ribosomal protein L7 248 0 3 1.3418115
67 S10A8_HUMAN (P05109) Protein S100-A8 93 0 3 1.3418115
68 RL12_HUMAN (P30050) 60S ribosomal protein L12 165 0 3 1.3418115
69 TBB1_HUMAN (Q9H4B7) Tubulin beta-1 chain 451 0 3 1.3418115
70 TAGL2_HUMAN (P37802) Transgelin-2 199 0 3 1.3418115
71 LDHA_HUMAN (P00338) L-lactate dehydrogenase A chain 332 0 3 1.3418115
72 DHSA_HUMAN (P31040) Succinate dehydrogenase [ubiquinone]
flavoprotein subunit, mitochondrial
664 0 3 1.3418115
73 S10A9_HUMAN (P06702) Protein S100-A9 114 0 3 1.3418115
74 TBA1A_HUMAN (Q71U36) Tubulin alpha-1 A chain 451 0 3 1.3418115
75 FIBA_HUMAN (P02671) Fibrinogen alpha chain 866 0 4 1.6480523
76 CEAM5_HUMAN (P06731) Carcinoembryonic antigen-related cell
adhesion molecule 5
702 0 4 1.6480523
77 RL1D1_HUMAN (O76021) Ribosomal L1 domain-containing protein 1 490 0 4 1.6480523
78 1433B_HUMAN (P31946) 14–3-3 protein beta/alpha 246 0 5 1.9009786
79 ACTN1_HUMAN (P12814) Alpha-actinin-1 892 1 10 1.9060767
80 DEF1_HUMAN (P59665) Neutrophil defensin 1 94 1 13 2.2513044
81 CH60_HUMAN (P10809) 60 kDa heat shock protein, mitochondrial 573 2 23 2.5000084
82 H2B1C_HUMAN (P62807) Histone H2B type 1-C/E/F/G/I 126 0 9 2.620238
83 H31_HUMAN (P68431) Histone H3.1 136 0 13 3.1011611
84 TBB5_HUMAN (P07437) Tubulin beta chain 444 0 13 3.1011611
Expression levels of these 84 proteins were more than two-fold higher or lower in cancer regions compared to non-cancer regions of CRC samples
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Results
Protein identification and profiles in cancer
and non-cancer regions of CRC tissue
To investigate the molecular profile of proteins expressed in
relation to cancer progression, we performed shotgun proteo-
mic analysis using FFPE CRC tissue. We used manual dissec-
tion to separate the cancer regions and non-cancer regions
from FFPE CRC tissues and examined the protein expression
not only in cells but also in the stromal tissue surrounding cells
(Fig. 1).We successfully identified proteins in both cancer and
non-cancer regions of FFPE tissues (Table 1). Figure 2 shows
the Venn map for the proteins identified.
Semiquantitative comparison of proteins identified
in cancer and non-cancer regions of CRC tissue
We next performed a label-free semiquantitative method
based on spectral counting to identify proteins with modified
Fig. 4 Analysis of GO cellular
components of identified
proteins. Protein assignments to
GO cellular component categories
are shown only for significant
categories (p < 0.05)
Table 4 Proteins categorized as
extracellular region proteins No. Accession number and description Fold change (Rsc)
1 (Q9Y6R7) IgGFc-binding protein −3.3070855
2 (P02452) Collagen alpha-1(I) chain −2.9751214
3 (Q02817) Mucin-2 −2.1989951
4 (O43707) Alpha-actinin-4 −1.8101074
5 (P01275) Glucagon −1.8101074
6 (A8K7I4) Calcium-activated chloride channel regulator 1 −1.3937233
7 (Q13751) Laminin subunit beta-3 −1.2777305
8 (Q8TD08) Mitogen-activated protein kinase 15 −1.2777305
9 (P98160) Basement membrane-specific heparan sulfate proteoglycan core protein −1.2777305
10 (P21333) Filamin-A −1.2777305
11 (P12110) Collagen alpha-2(VI) chain −1.2777305
12 (P02766) Transthyretin −1.2777305
13 (P00918) Carbonic anhydrase 2 −1.2777305
14 (O95994) Anterior gradient protein 2 homolog −1.1244392
15 (P62937) Peptidyl-prolyl cis-trans isomerase A 1.05112197
16 (P07355) Annexin A2 1.26663565
17 (P04075) Fructose-bisphosphate aldolase A 1.34181152
18 (P02671) Fibrinogen alpha chain 1.64805231
19 (P12814) Alpha-actinin-1 1.90607666
20 (P59665) Neutrophil defensin 1 2.25130442
21 (P10809) 60 kDa heat shock protein, mitochondrial 2.50000843
Twenty-one proteins that were differentially expressed in cancer regions of CRC samples were classified as
extracellular region proteins by gene ontology analysis
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expression levels in the cancer region. The Rsc value was
plotted against the corresponding protein (x-axis) in increasing
order from left to right for proteins identified in the cancer and
non-cancer regions. Positive and negative Rsc values indicate
increased and decreased expression, respectively, in the cancer
region. In Fig. 3, the NSAF value (bar) was plotted against the
corresponding protein (x-axis) and the NSAF values of the
cancer regions (black bar) and non-cancer regions (gray bar).
Proteins are indicated above and below the x-axis. Proteins
with either a high positive or negative Rsc value were consid-
ered as potential early detection markers for CRC.
A total of 84 differentially expressed proteins were identi-
fied in the cancer regions (Table 3). Representative proteins
that were upregulated included known tumor markers such as
60 kDa heat shock protein (HSP60) and carcinoembryonic
antigen-related cell adhesion molecule 5 (CEAM5, also
known as CEA). By contrast, expression levels of housekeep-
ing proteins such as β-actin and histone H4 did not change.
Functional annotation of differentially expressed proteins
in cancer regions of CRC tissue
DAVID was used to perform GO analyses for the differential-
ly expressed proteins identified for each cellular component
(Fig. 4). Functional annotations were counted by normalizing
to the total number of identified proteins. Based on the cellular
component classification, we focused on 21 proteins classified
in the extracellular region, which could potentially be detected
in the blood of patients with CRC (Table 4).
Fig. 5 qPCR analysis of spectral counting results. Aldolase A,
cyclophilin A, and annexin A2 were selected for confirmation.
Expression levels of aldolase A, cyclophilin A, and annexin A2 mRNA
were significantly higher in cancer compared to non-cancer regions (a–c).
*p < 0.05, **p < 0.001
Fig. 6 IHC validation of spectral
counting results. Expression
levels of aldolase A, cyclophilin
A, and annexin A2were validated
by IHC. Representative images of
non-cancer regions (a, d, and g)
and cancer regions (b, e, and h).
Graphs of IHC scores are shown
in (c), (f), and (i). Cancer regions
showed significantly stronger
expression of these three proteins,
which is consistent with spectral
counting data. *p < 0.05;
**p < 0.001. Original
magnification, 100×; insets, 400×
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qRT-PCR analysis of aldolase A, cyclophilin A,
and annexin A2 in cancer and non-cancer regions of CRC
tissue
Fructose-bisphosphate aldolase A (aldolase A), peptidyl-
prolyl cis-trans isomerase A (also known as cyclophilin
A), and annexin A2 were upregulated in cancer regions
(Table 3) and consequently selected as candidate diagnos-
tic biomarkers. To confirm the higher expression levels of
the candidate proteins in cancer regions compared to non-
cancer regions, we performed qRT-PCR analysis.
Expression levels of the mRNAs for these proteins were
significantly higher in cancer compared to non-cancer re-
gions (Fig. 5a–c).
IHC analysis of aldolase A, cyclophilin A, and annexin A2
in cancer and non-cancer regions of CRC tissue
We next performed IHC analysis of the three candidate pro-
teins for validation with tissues from 45 CRC cases (Table 2).
IHC analysis revealed that expression levels of all three pro-
teins were significantly higher in cancer regions compared to
non-cancer regions (Fig. 6).
Expression of aldolase A, cyclophilin A, and annexin A2
in CRC cell lines
To investigate whether the candidate proteins were suitable as
biomarkers, their mRNA and protein expression levels in CRC
cell lines were determined by qRT-PCR analysis and western
blotting. All tested cell lines expressed the three candidate pro-
teins, and their expression levels in CRC cells tended to be higher
than in normal colon epithelial cells (Fig. 7a–d). Aldolase Awas
not detected in the culture medium of the three CRC cell lines,
but it was detected in normal colon epithelial cells (Fig. 7e, upper
panel). Cyclophilin Awas not detected in the culture medium of
any cell lines (Fig. 7e, middle panel). The level of annexin A2 in
the culture medium appeared to depend on the level of annexin
A2 in the cell extract for each cell line (Fig. 7e, lower panel).
Finally, we detected aldolase A in normal human serum and
confirmed that the level depended on the loaded serum volume
(Fig. 7f, lane 1–3).
Discussion
In this study, we used a gel-free LC-MS-based proteomics
approach to identify potential biomarkers for cancer in FFPE
Fig. 7 Expression of the three candidate proteins in CRC cell lines.
Expression levels of aldolase A, cyclophilin A, and annexin A2 were
examined by qRT-PCR and western blot. Expression levels of aldolase
A (a), cyclophilin A (b), and annexin A2 (c) mRNA in CRC cells were
almost all significantly higher than in normal colon epithelium. *p < 0.05;
**p < 0.001. Expression levels of the three candidate proteins in cell
extracts from CRC cell lines were similar to mRNA expression levels
(d). Aldolase Awas only detected in the culture medium of normal colon
epithelium (e, upper panel). Cyclophilin Awas not detected in any of the
examined culture medium samples (e, middle panel). The level of
annexin A2 in the culture medium appeared to depend on the level in
the cell extract for each cell line (e, lower panel). Aldolase Awas detected
in human normal serum, and the level of aldolase A detected depended on
the volume of serum loaded (f, lane 1, 10 μg serum; lane 2, 20 μg serum;
lane 3, 30 μg serum)
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CRC tissues. We used semiquantitative methods based on
spectral counting to detect 84 proteins in which expression
levels were altered >2-fold in cancer compared to non-
cancer regions of CRC tissue (Table 3). CEA, a known tumor
marker used in diagnostic blood tests for CRC, was among
these proteins. Thus, the approach used in this study could
potentially be used to identify novel biomarker candidates.
To identify early detection markers for CRC that can be
detected by diagnostic blood tests, we focused on proteins in
the Bextracellular region^ category of cellular components
based on the results of GO analysis (Table 4). These proteins
are secreted into the extracellular space and thus may poten-
tially be detected in blood. These criteria led us to select al-
dolase A, cyclophilin A, and annexin A2 as candidates. We
did not include HSP60, neutrophil defensin1, or alpha-actinin-
1, because previous reports had already suggested that these
proteins might be biomarkers for CRC [26–29].
Validation studies revealed that mRNA and protein expres-
sion levels of the three candidate proteins were significantly
higher in the cancer region compared to non-cancer regions
(Figs. 5 and 6). Moreover, to evaluate whether these proteins
were useful as biomarkers, we also investigated their mRNA
and protein expression levels in CRC cell lines and secretion
of the proteins into the medium. Cyclophilin Awas not secret-
ed into the culture medium of all tested CRC cell lines
(Fig. 7e). Thus, cyclophilin A is not suitable as a diagnostic
blood tumor marker. On the other hand, annexin A2 expres-
sion in SW480 cells derived from the primary tumor site of a
CRC patient was higher than expression in SW620 cells that
were established from a metastatic site in the same patient
(Fig. 7c–e). Decreased annexin A2 expression in cancer cells
could play a role in the progression andmetastasis of CRC and
may be useful for predicting metastasis.
Although mRNA and protein expression of aldolase A
were detected in all tested cell lines (Fig. 7a and d), aldolase
A protein was not detected in the culture medium of the three
CRC cell lines, while it was clearly detected in the culture
medium of normal colon epithelial cells (Fig. 7e). Moreover,
aldolase A was detected in normal human serum (Fig. 7f).
These results suggest that secretion of aldolase A may be
suppressed by dysfunction of aldolase A due to accumulated
genetic mutations during the carcinogenesis process of CRC.
Therefore, decreased aldolase A levels in blood may be useful
as a biomarker for the early diagnosis of CRC.
Aldolase A is a glycolytic enzyme and contributes to var-
ious cellular functions related to muscle maintenance, cell
shape and mobility regulation, striated muscle contraction,
actin filament organization, and ATP biosynthesis [30–40].
There are several reports of elevated expression of aldolase
A in the serum of patients with malignant tumors, such as
those with lung and renal cancer [41, 42]. However, the
expression kinetics and functions of aldolase A in CRC are
not well understood. To our knowledge, this is the first report
of decreased secretion of aldolase A in CRC. Thus, further
studies are necessary to clarify the decrease in aldolase A
levels in the blood of CRC patients in order to determine if
this protein can be used as an early detection biomarker for
CRC.
Conclusion
In conclusion, we identified 248 proteins from FFPE CRC tis-
sues using global shotgun proteomics. A label-free semiquanti-
tative method based on spectral counting and GO identified 21
candidate early detection biomarkers for CRC that could poten-
tially be detected in blood. Validation studies revealed that
cyclophilin A, annexin A2, and aldolase A expression levels
were significantly higher in cancer compared to non-cancer re-
gions. In vitro studies showed that secretion of aldolase A into
the culture medium was clearly suppressed in CRC cancer cells
to normal colon epithelium. Finally, aldolase A may play an
important role in the carcinogenesis process of CRC and may
be useful as an early detection biomarker for CRC.
Acknowledgments We thank Mr. K. Teduka and Mr. T. Fujii for tech-
nical assistance (Department of Integrated Diagnostic Pathology). This
work was supported by a Grant-in-Aid for Scientific Research (C, No.
15 K09054 to T. Yamamoto) and also in part by the MEXT-Supported
Program of the Strategic Research Foundation at Private Universities
(2014-2018) (S1411037).
Compliance with ethical standards
Conflicts of interest None.
Open Access This article is distributed under the terms of the Creative
Commons Attr ibution 4.0 International License (http: / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Kuusela P, Jalanko H, Roberts P, Sipponen P, Mecklin JP, Pitkanen
R, Makela O. Comparison of CA 19-9 and carcinoembryonic anti-
gen (CEA) levels in the serum of patients with colorectal diseases.
Br J Cancer. 1984;49:135–9.
2. Zamcheck N, Pusztaszeri G. CEA, AFP and other potential tumor
markers. CA Cancer J Clin. 1975;25:204–14.
3. Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry:
past, present, and future. The journal of histochemistry and cytochem-
istry: official journal of the Histochemistry Society. 1997;45:327–43.
4. Tourtellotte WW, Verity AN, Schmid P, Martinez S, Shapshak P.
Covalent binding of formalin fixed paraffin embedded brain tissue
13604 Tumor Biol. (2016) 37:13595–13606
sections to glass slides suitable for in situ hybridization. J Virol
Methods. 1987;15:87–99.
5. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of
HER2 gene amplification by chromogenic in situ hybridization
(CISH) in archival breast carcinoma. Modern pathology: an official
journal of the United States and Canadian Academy of Pathology,
Inc. 2002;15:657–65.
6. D.A. Prieto, B.L. Hood, M.M. Darfler, T.G. Guiel, D.A. Lucas, T.P.
Conrads, T.D. Veenstra, D.B. Krizman, Liquid tissue: proteomic pro-
filing of formalin-fixed tissues. BioTechniques Suppl. 2005. 32–35.
7. Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA,
Ringeisen BR, Sesterhenn IA, Conrads TP, Veenstra TD,
Krizman DB. Proteomic analysis of formalin-fixed prostate cancer
tissue. Molecular & cellular proteomics: MCP. 2005;4:1741–53.
8. Hood BL, Conrads TP, Veenstra TD. Unravelling the proteome of
formalin-fixed paraffin-embedded tissue. Briefings in functional
genomics & proteomics. 2006;5:169–75.
9. Hood BL, Conrads TP, Veenstra TD. Mass spectrometric analysis
of formalin-fixed paraffin-embedded tissue: unlocking the prote-
ome within. Proteomics. 2006;6:4106–14.
10. Guo T, Wang W, Rudnick PA, Song T, Li J, Zhuang Z, Weil RJ,
DeVoe DL, Lee CS, Balgley BM. Proteome analysis of microdis-
sected formalin-fixed and paraffin-embedded tissue specimens. The
journal of histochemistry and cytochemistry : official journal of the
Histochemistry Society. 2007;55:763–72.
11. Kislinger T, Cox B, Kannan A, Chung C, Hu P, Ignatchenko A,
Scott MS, Gramolini AO, Morris Q, Hallett MT, Rossant J, Hughes
TR, Frey B, Emili A. Global survey of organ and organelle protein
expression in mouse: combined proteomic and transcriptomic pro-
filing. Cell. 2006;125:173–86.
12. Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Mining the archival
formalin-fixed paraffin-embedded tissue proteome: opportunities
and challenges. Mol BioSyst. 2008;4:712–20.
13. Scicchitano MS, Dalmas DA, Boyce RW, Thomas HC, Frazier KS.
Protein extraction of formalin-fixed, paraffin-embedded tissue en-
ables robust proteomic profiles by mass spectrometry. The journal
of histochemistry and cytochemistry : official journal of the
Histochemistry Society. 2009;57:849–60.
14. Sprung Jr RW, Brock JW, Tanksley JP, Li M, Washington MK,
Slebos RJ, Liebler DC. Equivalence of protein inventories obtained
from formalin-fixed paraffin-embedded and frozen tissue in multi-
dimensional liquid chromatography-tandem mass spectrometry
shotgun proteomic analysis. Molecular & cellular proteomics:
MCP. 2009;8:1988–98.
15. Naidoo K, Jones R, Dmitrovic B,Wijesuriya N, Kocher H, Hart IR,
Crnogorac-Jurcevic T. Proteome of formalin-fixed paraffin-embed-
ded pancreatic ductal adenocarcinoma and lymph node metastases.
J Pathol. 2012;226:756–63.
16. Paulo JA, Lee LS, Banks PA, Steen H, Conwell DL. Proteomic
analysis of formalin-fixed paraffin-embedded pancreatic tissue
using liquid chromatography tandem mass spectrometry.
Pancreas. 2012;41:175–85.
17. Jiang X, Feng S, Tian R, Ye M, Zou H. Development of efficient
protein extraction methods for shotgun proteome analysis of
formalin-fixed tissues. J Proteome Res. 2007;6:1038–47.
18. Hamilton SR, Aaltonen LA. Pathology and genetics of tumours of
the digestive system. In: Kleihues P, Sobin LH, editors. World
health organization classification of tumours. Lyon: IARCPress;
2000.
19. Bluemlein K, Ralser M. Monitoring protein expression in whole-
cell extracts by targeted label- and standard-free LC-MS/MS. Nat
Protoc. 2011;6:859–69.
20. Kawamura T, Nomura M, Tojo H, Fujii K, Hamasaki H, Mikami S,
Bando Y, Kato H, Nishimura T. Proteomic analysis of laser-
microdissected paraffin-embedded tissues: (1) stage-related protein
candidates upon non-metastatic lung adenocarcinoma. J Proteome.
2010;73:1089–99.
21. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza
A, Sevinsky JR, Resing KA, Ahn NG. Comparison of label-free
methods for quantifying human proteins by shotgun proteomics.
Molecular & cellular proteomics : MCP. 2005;4:1487–502.
22. Zybailov B, ColemanMK, Florens L,WashburnMP. Correlation of
relative abundance ratios derived from peptide ion chromatograms
and spectrum counting for quantitative proteomic analysis using
stable isotope labeling. Anal Chem. 2005;77:6218–24.
23. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC,
Lempicki RA. DAVID: database for annotation, visualization, and
integrated discovery. Genome Biol. 2003;4:P3.
24. da Huang W, Sherman BT, Lempicki RA. Systematic and integra-
tive analysis of large gene lists using DAVID bioinformatics re-
sources. Nat Protoc. 2009;4:44–57.
25. da Huang W, Sherman BT, Lempicki RA. Bioinformatics enrich-
ment tools: paths toward the comprehensive functional analysis of
large gene lists. Nucleic Acids Res. 2009;37:1–13.
26. Hamelin C, Cornut E, Poirier F, Pons S, Beaulieu C, Charrier JP,
Haidous H, Cotte E, Lambert C, Piard F, Ataman-Onal Y, Choquet-
Kastylevsky G. Identification and verification of heat shock protein
60 as a potential serum marker for colorectal cancer. The FEBS
journal. 2011;278:4845–59.
27. van den Broek I, Sparidans RW, Engwegen JY, Cats A, Depla AC,
Schellens JH, Beijnen JH. Evaluation of human neutrophil peptide-
1, -2 and -3 as serum markers for colorectal cancer. Cancer bio-
markers : section A of Disease markers. 2010;7:109–15.
28. Kemik O, Kemik AS, Sumer A, Begenik H, Purisa S, Tuzun S.
Human neutrophil peptides 1, 2 and 3 (HNP 1-3): elevated serum
levels in colorectal cancer and novel marker of lymphatic and hepatic
metastasis. Human & experimental toxicology. 2013;32:167–71.
29. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C,
Gaustadnes M, Hein AM, Kruhoffer M, Laurberg S, Borre M,
Wang K, Brunak S, Krainer AR, Torring N, Dyrskjot L,
Andersen CL, Orntoft TF. Alternative splicing in colon, bladder,
and prostate cancer identified by exon array analysis. Molecular &
cellular proteomics : MCP. 2008;7:1214–24.
30. Kusakabe T, Motoki K, Hori K. Mode of interactions of human
aldolase isozymes with cytoskeletons. Arch Biochem Biophys.
1997;344:184–93.
31. Harris SJ, Winzor DJ. Enzyme kinetic evidence of active-site in-
volvement in the interaction between aldolase and muscle myofi-
brils. Biochim Biophys Acta. 1987;911:121–6.
32. Carr D, Knull H. Aldolase-tubulin interactions: removal of tubulin
C-terminals impairs interactions. Biochem Biophys Res Commun.
1993;195:289–93.
33. St-Jean M, Izard T, Sygusch J. A hydrophobic pocket in the active
site of glycolytic aldolase mediates interactions with Wiskott-
Aldrich syndrome protein. J Biol Chem. 2007;282:14309–15.
34. Arnold H, Pette D. Binding of glycolytic enzymes to structure pro-
teins of the muscle. European journal of biochemistry/FEBS.
1968;6:163–71.
35. Walsh JL, Knull HR. Heteromerous interactions among glycolytic
enzymes and of glycolytic enzymes with F-actin: effects of poly
(ethylene glycol). Biochim Biophys Acta. 1988;952:83–91.
36. Clarke FM, Masters CJ. On the association of glycolytic enzymes
with structural proteins of skeletal muscle. Biochim Biophys Acta.
1975;381:37–46.
Tumor Biol. (2016) 37:13595–13606 13605
37. Knull HR, Walsh JL. Association of glycolytic enzymes with the
cytoskeleton. Curr Top Cell Regul. 1992;33:15–30.
38. Walsh JL, Keith TJ, Knull HR. Glycolytic enzyme interactions with
tubulin and microtubules. Biochim Biophys Acta. 1989;999:64–70.
39. Tochio T, Tanaka H, Nakata S, Hosoya H. Fructose-1,6-
bisphosphate aldolase a is involved in HaCaT cell migration by
inducing lamellipodia formation. J Dermatol Sci. 2010;58:123–9.
40. Lu M, Holliday LS, Zhang L, Dunn Jr WA, Gluck SL. Interaction
between aldolase and vacuolar H + −ATPase: evidence for direct
coupling of glycolysis to the ATP-hydrolyzing proton pump. J Biol
Chem. 2001;276:30407–13.
41. Asaka M, Kimura T, Meguro T, Kato M, Kudo M, Miyazaki T,
Alpert E. Alteration of aldolase isozymes in serum and tissues of
patients with cancer and other diseases. J Clin Lab Anal. 1994;8:
144–8.
42. Takashi M, ZhuY, NakanoY,Miyake K, Kato K. Elevated levels of
serum aldolase a in patients with renal cell carcinoma. Urol Res.
1992;20:307–11.
13606 Tumor Biol. (2016) 37:13595–13606
